Evidence map›Paper›PMID 32997053›Full record

ArticleRevista da Sociedade Brasileira de Medicina Tropical2020

Cost analysis of smear microscopy and the Xpert assay for tuberculosis diagnosis: average turnaround time.

Lida Jouca de Assis Figueredo, Silvana Spíndola de Miranda, Lucas Benício Dos Santos, Caroline Gontijo Gonçalves Manso, Valéria Martins Soares, Suely Alves, Maria Cláudia Vater, Afrânio Lineu Kritski, Wânia da Silva Carvalho, Cristiane Menezes de Pádua and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Revista da Sociedade Brasileira de Medicina Tropical, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Emergence ofFrontiers in public health · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Case report: Difficult diagnosis ofFrontiers in oncology · 2024
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Lida Jouca de Assis FigueredoUniversidade Federal de Minas Gerais, Laboratório de Pesquisa em Micobactérias, Belo Horizonte, MG, Brasil.
Silvana Spíndola de MirandaUniversidade Federal de Minas Gerais, Grupo de Pesquisa em Micobacterioses, Faculdade de Medicina, Belo Horizonte, MG, Brasil.ORCID http://orcid.org/0000-0001-7245-4472
Lucas Benício Dos SantosUniversidade Federal de Minas Gerais, Laboratório de Pesquisa em Micobactérias, Belo Horizonte, MG, Brasil.
Caroline Gontijo Gonçalves MansoUniversidade Federal de Minas Gerais, Laboratório de Pesquisa em Micobactérias, Belo Horizonte, MG, Brasil.
Valéria Martins SoaresFundação Hospitalar do Estado de Minas Gerais, Hospital Júlia Kubistchek, Laboratório de Microbiologia, Belo Horizonte, MG, Brasil.
Suely AlvesUniversidade Federal do Rio de Janeiro, Programa Acadêmico de Tuberculose, Rio de Janeiro, RJ, Brasil.
Maria Cláudia VaterUniversidade Federal do Rio de Janeiro, Programa Acadêmico de Tuberculose, Rio de Janeiro, RJ, Brasil.
Afrânio Lineu KritskiUniversidade Federal do Rio de Janeiro, Programa Acadêmico de Tuberculose, Rio de Janeiro, RJ, Brasil.
Wânia da Silva CarvalhoUniversidade Federal de Minas Gerais, Faculdade de Farmácia, Belo Horizonte, MG, Brasil.
Cristiane Menezes de PáduaUniversidade Federal de Minas Gerais, Faculdade de Farmácia, Belo Horizonte, MG, Brasil.
Isabela Neves de AlmeidaUniversidade Federal de Minas Gerais, Laboratório de Pesquisa em Micobactérias, Belo Horizonte, MG, Brasil.
Universidade Federal de Minas Gerais · BRUniversidade Federal do Rio de Janeiro · BRFundação Hospitalar do Estado de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRapid and accurate tuberculosis detection is critical for improving patient diagnosis and decreasing tuberculosis transmission. Molecular assays can significantly increase laboratory costs; therefore, the average time and economic impact should be evaluated before implementing a new technology. The aim of this study was to evaluate the cost and average turnaround time of smear microscopy and Xpert assay at a university hospital.

methodsThe turnaround time and cost of the laboratory diagnosis of tuberculosis were calculated based on the mean cost and activity based costing (ABC).

resultsThe average turnaround time for smear microscopy was 16.6 hours while that for Xpert was 24.1 hours. The Xpert had a mean cost of USD 17.37 with an ABC of USD 10.86, while smear microscopy had a mean cost of USD 13.31 with an ABC of USD 6.01. The sensitivity of smear microscopy was 42.9% and its specificity was 99.1%, while the Xpert assay had a sensitivity of 100% and a specificity of 96.7%.

conclusionsThe Xpert assay has high accuracy; however, the turnaround time and cost of smear microscopy were lower than those of Xpert.

Indexed as

Biological AssayCosts and Cost AnalysisHumansMicroscopyMycobacterium tuberculosisPathology, MolecularSensitivity and SpecificityTuberculosisTuberculosis, Pulmonary

Identifiers

PMID32997053
PMCPMC7523521
OpenAlexW3088754216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.